[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Dr_Oncologista Aya Mohamed | MSc, MD 🎗 Aya Mohamed | MSc, MD 🎗 posts on X about breast cancer, iv, mothers, cohort the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1157309656123023361/interactions)  - X Week XXXXXX +143,488% - X Year XXXXXX +96% ### Mentions: XX [#](/creator/twitter::1157309656123023361/posts_active)  ### Followers: XXXXX [#](/creator/twitter::1157309656123023361/followers)  - X Week XXXXX +4.10% - X Months XXXXX +25% - X Year XXXXX +40% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1157309656123023361/influencer_rank)  ### Social Influence [#](/creator/twitter::1157309656123023361/influence) --- **Social topic influence** [breast cancer](/topic/breast-cancer), [iv](/topic/iv), [mothers](/topic/mothers), [cohort](/topic/cohort), [pam](/topic/pam), [efs](/topic/efs), [promising](/topic/promising), [aya](/topic/aya) #127, [os](/topic/os) #141 ### Top Social Posts [#](/creator/twitter::1157309656123023361/posts) --- Top posts by engagements in the last XX hours "PLANET: Low-dose pembrolizumab in neoadjuvant therapy for triple-negative #BreastCancer Showing that conducting quality clinical research developed and funded by government entities shouldn't be a first-world privilege. @OncoAlert #ESMO25 #bcsm" [X Link](https://x.com/Dr_Oncologista/status/1979357573347496210) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T01:23Z 1236 followers, XXX engagements "In a bold design researchers from New Delhi proposed neoadjuvant treatment of patients with TNBC with Pembrolizumab XX mg IV every X weeks And evaluate what would happen in terms of PCR But before the results some points of divergence with the KN-522:" [X Link](https://x.com/Dr_Oncologista/status/1979357577134960931) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T01:23Z 1234 followers, XX engagements "Patients under XX yrs of age with HR+ breast cancer (HER2- or HER2+) stages I-III who wish to become pregnant were enrolled in a single-arm trial to discontinue adjuvant endocrine therapy for up to X yrs become mothers and then resume treatment until completion (5-10 yrs)" [X Link](https://x.com/Dr_Oncologista/status/1979361565444051376) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T01:39Z 1234 followers, XX engagements "With the control done historically with the women of SOFT-TEXT (for ethical reasons it could not be a randomized study)" [X Link](https://x.com/Dr_Oncologista/status/1979361571056054572) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T01:39Z 1234 followers, XX engagements "VIKTORIA-1 Study Targeting HR+/HER2- PIK3CA wild-type metastatic/recurrent #breastcancer (after CDK4/6 inhibitor) Gedatolisib + Fulvestrant Palbociclib vs Fulvestrant alone PFS: @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979470795429531976) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T08:53Z 1254 followers, 1437 engagements "VIKTORIA-1 study evaluating Gedatosib a PAM inhibitor of the PI3K-AKT-mTOR pathway in association with FULV +- Palbociclib Positive study with PFS gain in this PIK3CAwt cohort will we still need to test @OncoAlert #ESMO25 @myESMO" [X Link](https://x.com/Dr_Oncologista/status/1979522350325629040) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T12:18Z 1254 followers, XXX engagements "DESTINY-Breast11 trial reported favorable EFS results with a XXXX% improvement in pCR when T-DXd was used as neoadjuvant chemotherapy followed by THP. #ESMO25 @OncoAlert" [X Link](https://x.com/Dr_Oncologista/status/1979570430680641921) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T15:29Z 1254 followers, XXX engagements "TROPION-Breast02 Another anti-TROP2 now Datopotamab Deruxtecan also in this same 1L scenario in patients not eligible for immunotherapy No crossover was allowed (Dato-DXd has no OS in subsequent lines)and about XX% of population with relapse interval 6m @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979861068509024540) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T10:43Z 1253 followers, XXX engagements "DESTINY-Breast05 Adjuvant study in residual disease with TDXd after neoadjuvance in HER2+ disease Patients at highest risk in the inclusion criteria control arm along the lines of the KATHERINE study @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979601106381553800) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T17:30Z 1254 followers, 1188 engagements "Another new standard of care for triple-negative first-line cancers A phase III trial comparing Dato-DXd vs. chemotherapy in patients with untreated metastatic/recurrent TNBC who were ineligible for ICI. @OncoAlert #ESMO25 #bcsm" [X Link](https://x.com/Dr_Oncologista/status/1979850310568018340) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T10:01Z 1252 followers, 2543 engagements "PSMAddition Scott Tagawa presents PIII trial of Lu-PSMa -XXX + ADT + ARPI in PSMA positive HSPC Discrete gain in SLPr immature SG @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979946057984291230) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T16:21Z 1252 followers, XXX engagements "🔹Innovative molecule with demonstrated efficacy control with XX Chinese that performed the same as KN407 still without OS data. 🔹 The global HARMONI-3 study of 1L NSCLC independent of histology is awaited for confirmation and validation of the data. @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1980161238421414259) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T06:36Z 1254 followers, XXX engagements "PSMAddition 1st line castration-sensitive metastatic prostate cancer Androgen Deprivation Therapy Antiandrogen Therapy +/- Lutecio177-PSMA617 Significant benefit for radiological progression-free survival ➡ Immature Overall Survival @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1980167548470714586) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T07:01Z 1254 followers, XXX engagements "Low TGI oral session CHECKMATE 8HW data updated Result only for 1st line IPI + NIVO with relevant numerical difference in SLP in relative to NIVO Global Survival (Here in all tto lines ) Still Immature Breakwater analysis according to CTDNA dynamics @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1980228980843352536) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T11:05Z 1252 followers, 1664 engagements "the beautiful data from POSITIVE now mature at X yrs Dr. Fedro Peccatori and this group of young #BreastCancer experts are conducting one of the most exciting studies of the decade. @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979361561807643080) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T01:39Z 1244 followers, XXX engagements "evERA-BC trial; Giredestrant (oral SERD) + everolimus vs SOC ET + everolimus in ER+/HER2 advanced breast cancer previously treated with CDK4/6i ESR1m population: median PFS XXXX vs XXXX mo HR XXXX (p0.0001) @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979465392725856673) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T08:31Z 1237 followers, XXX engagements "evERA very interesting study competitive with the main combination in this scenario at the moment: Imlu + Abema (EMBER-3) First phase X to evaluate the oral SERD + mTOR inhibitor combination In a population of post-PD patients iCDK4/6 @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979549214645375421) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T14:04Z 1245 followers, XXX engagements "Establishing a new standard of care DESTINY-Breast05 A phase III trial comparing T-DXd (trastuzumab deruxtecan) vs. T-DM1 in high-risk HER2-positive early breast cancer with residual invasive disease (non-pCR) after neoadjuvant chemotherapy. @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979569481992044986) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T15:25Z 1245 followers, XXX engagements "Results after CDK4/6 inhibitor treatment including the VIKTORIA-1 and eveERA-BC trials #ESMO25 @OncoAlert" [X Link](https://x.com/Dr_Oncologista/status/1979471281155097086) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T08:55Z 1247 followers, XXX engagements "OptiTROP-Breast02 Chinese study with new anti-TROP2 ADC after depleting HT in RH+ patients. Sacituzumab tirumotecan Results from the randomized multi-center phase Ill #ESMO25 @OncoAlert" [X Link](https://x.com/Dr_Oncologista/status/1979520169710915622) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T12:09Z 1247 followers, XXX engagements "evERA very interesting study competitive with the main combination in this scenario at the moment: Imlu + Abema (EMBER-3) First phase X to evaluate the oral SERD + mTOR inhibitor combination In a population of post-PD patients iCDK4/6" [X Link](https://x.com/Dr_Oncologista/status/1979548277201854602) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T14:01Z 1247 followers, XXX engagements "CARES-009 phase X study of perioperative camrelizumab and rivoceranib for HCC And data on perioperative immunotherapy and antiangiogenic therapy in HCC X cycles of preoperative Camrelizumab and Rivoceranib @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979867917354488034) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T11:11Z 1246 followers, XXX engagements "Positive study for PFS with gain compared to QT-10 regardless of the PD-L1 status assessed OS still immature safety data without significant increase in AE including bleeding risk" [X Link](https://x.com/Dr_Oncologista/status/1980160993973203367) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T06:35Z 1247 followers, XX engagements "FOG001 a beta-catenin TCF interaction inhibitor is effective in treating desmoid tumors even in patients previously treated with gamma-secretase inhibitors. It's showing promise. @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979215012984987985) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-17T15:56Z 1252 followers, XXX engagements "DeLLphi-303: Phase 1b study evaluating tarlatamab combined with CT+10 in extensive small cell lung disease 🔹Interesting SG result in 1st @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979491386207400432) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T10:14Z 1252 followers, XXX engagements "A new standard of care for first-line triple-negative chemotherapy ASENT-03 Study: A Phase III trial comparing sacituzumab govitecan (SG)** with chemotherapy in patients with untreated metastatic TNBC who are ineligible for PD-L1 inhibitors @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979851597992935603) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T10:06Z 1254 followers, XXX engagements "Richard Finn presents the results of phase X IMbrave152/SkYSCRAPER-14 study at @myESMO Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced HCC @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979869336631390382) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T11:16Z 1252 followers, XXX engagements "OptiTROP-Lung04 Sacituzumab Tirumotecan an anti-TROP2 ADC in 2L in EGFRmut NSCLC after PD to TKI Without TROP2 biomarker analysis XX% received 3rd Generation TKI Positive study for PFS and OS with median not reached with XX% risk reduction @OncoAlert #ESMO25 #lcsm" [X Link](https://x.com/Dr_Oncologista/status/1980163483590132197) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T06:45Z 1252 followers, XXX engagements "Advanced Bladder Cancer 1st line and HER2 expressed 1+ 2+ or 3+ Disitamabe Vedotin + Toripalimabe VSplatinum-based QT Significant benefit in SLP Some HER2 expression is present in up to XX% of cases Enriched in high urothelial treatment @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1980171181312586066) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T07:16Z 1252 followers, XXX engagements "Encouraging Results for VT3989 in Advanced Solid Tumors Phase 1/2 study (NCT04665206) of VT3989 (a YAP/TEAD inhibitor) shows promising data: Strong Efficacy: Broad tumor shrinkage observed in mesothelioma patients at the optimized dose. @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1980186972741398900) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T08:18Z 1252 followers, XXX engagements "The QT interval appears to be important for improving ctDNA clearance and reducing the emergence of known resistant variants. The question is: Is this situation sustainable and does it relate to as-yet-unknown variants ZANZALITINIBE =TKI MULTIKINASE ATEZOLIZUMABE= ANTI PD-L1" [X Link](https://x.com/Dr_Oncologista/status/1980228984341463056) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T11:05Z 1252 followers, XX engagements "Phase III study of adjuvant ensartinib versus placebo for surgically resected ALK+ mutant non-small cell lung cancer (NSCLC). Ensartinib demonstrated a significant and statistically significant clinical and progression-free survival (DFS) benefit @OncoAlert #ESMO25 @Lung_Cancers" [X Link](https://x.com/Dr_Oncologista/status/1980265281919300011) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T13:30Z 1254 followers, XXX engagements "MonarchE trial - X year abemaciclib in early #breastcancer - shows a survival benefit (1.8% difference at X yrs) I was glad to see granularity in post-recurrence therapy data which are key in interpretating any survival benefit #ESMO25 @OncoAlert @myESMO #bcsm" [X Link](https://x.com/Dr_Oncologista/status/1979213560199753819) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-17T15:50Z 1246 followers, XXX engagements "The effects of HDAC inhibitors and PD-1 inhibitors. In liposarcoma the response rate was XX% for well-differentiated and dedifferentiated tumors. It is difficult to explain biologically why the combination is so effective @OncoAlert @myESMO #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979214516551311649) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-17T15:54Z 1246 followers, XXX engagements "Study evaluating multidisciplinary discussion (MDT) followed by induction chemotherapy + IO X XX and new MDT Most patients even those borderline for resection were operated on after QT + XX induction @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979494082838688098) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T10:25Z 1246 followers, XXX engagements "Presidential EVP from KN905 in MIBC at @myESMO with incredibly strong data. PathCR of XX% EFS and OS positive a game changing study continuation of treatment with EV in those with pCR Is cisplatin candidacy still relevant for MIBC @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979603650176766012) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-18T17:41Z 1247 followers, XXX engagements "DESTINY-Breast09 Updated PFS data in subgroup analysis of TDXd in 1L in HER2+ First presentation of efficacy data at this yrs ASCO CHAIRS RUPERT BARTSCH SEOCK @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979847237703520601) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T09:48Z 1247 followers, XXX engagements "ASENT-03 Study Sacituzumab Govitecan anti-TROP2 in 1L in TNBC not a candidate for immunotherapy It is worth noting that patients with a recurrence interval 6m were not included but the crossover allowed is beneficial since Saci-Gov has gained OS in 2L. @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1979854524228813230) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-19T10:17Z 1247 followers, XXX engagements "HARMONI-6 Study of Ivonescimab +QT versus 10+QT 1L in patients with PD-L1-independent squamous NSCLC in a Chinese population 🔹Independent of PD-L1 in Chinese population @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1980160979435450779) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-20T06:35Z 1247 followers, XXX engagements "future treatment of this patient population relies on combinations of novel SERDs/SERMs with other targeted agents particularly those inhibiting the PI3K/AKT/mTOR signaling pathway to successfully bypass the conventional 6-month PFS threshold. @OncoAlert #ESMO25" [X Link](https://x.com/Dr_Oncologista/status/1980566824812167215) [@Dr_Oncologista](/creator/x/Dr_Oncologista) 2025-10-21T09:28Z 1254 followers, 1275 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Dr_Oncologista Aya Mohamed | MSc, MD 🎗
Aya Mohamed | MSc, MD 🎗 posts on X about breast cancer, iv, mothers, cohort the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +143,488%
- X Year XXXXXX +96%
Mentions: XX #
Followers: XXXXX #
- X Week XXXXX +4.10%
- X Months XXXXX +25%
- X Year XXXXX +40%
CreatorRank: XXXXXXXXX #
Social Influence #
Social topic influence breast cancer, iv, mothers, cohort, pam, efs, promising, aya #127, os #141
Top Social Posts #
Top posts by engagements in the last XX hours
"PLANET: Low-dose pembrolizumab in neoadjuvant therapy for triple-negative #BreastCancer Showing that conducting quality clinical research developed and funded by government entities shouldn't be a first-world privilege. @OncoAlert #ESMO25 #bcsm"
X Link @Dr_Oncologista 2025-10-18T01:23Z 1236 followers, XXX engagements
"In a bold design researchers from New Delhi proposed neoadjuvant treatment of patients with TNBC with Pembrolizumab XX mg IV every X weeks And evaluate what would happen in terms of PCR But before the results some points of divergence with the KN-522:"
X Link @Dr_Oncologista 2025-10-18T01:23Z 1234 followers, XX engagements
"Patients under XX yrs of age with HR+ breast cancer (HER2- or HER2+) stages I-III who wish to become pregnant were enrolled in a single-arm trial to discontinue adjuvant endocrine therapy for up to X yrs become mothers and then resume treatment until completion (5-10 yrs)"
X Link @Dr_Oncologista 2025-10-18T01:39Z 1234 followers, XX engagements
"With the control done historically with the women of SOFT-TEXT (for ethical reasons it could not be a randomized study)"
X Link @Dr_Oncologista 2025-10-18T01:39Z 1234 followers, XX engagements
"VIKTORIA-1 Study Targeting HR+/HER2- PIK3CA wild-type metastatic/recurrent #breastcancer (after CDK4/6 inhibitor) Gedatolisib + Fulvestrant Palbociclib vs Fulvestrant alone PFS: @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T08:53Z 1254 followers, 1437 engagements
"VIKTORIA-1 study evaluating Gedatosib a PAM inhibitor of the PI3K-AKT-mTOR pathway in association with FULV +- Palbociclib Positive study with PFS gain in this PIK3CAwt cohort will we still need to test @OncoAlert #ESMO25 @myESMO"
X Link @Dr_Oncologista 2025-10-18T12:18Z 1254 followers, XXX engagements
"DESTINY-Breast11 trial reported favorable EFS results with a XXXX% improvement in pCR when T-DXd was used as neoadjuvant chemotherapy followed by THP. #ESMO25 @OncoAlert"
X Link @Dr_Oncologista 2025-10-18T15:29Z 1254 followers, XXX engagements
"TROPION-Breast02 Another anti-TROP2 now Datopotamab Deruxtecan also in this same 1L scenario in patients not eligible for immunotherapy No crossover was allowed (Dato-DXd has no OS in subsequent lines)and about XX% of population with relapse interval 6m @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-19T10:43Z 1253 followers, XXX engagements
"DESTINY-Breast05 Adjuvant study in residual disease with TDXd after neoadjuvance in HER2+ disease Patients at highest risk in the inclusion criteria control arm along the lines of the KATHERINE study @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T17:30Z 1254 followers, 1188 engagements
"Another new standard of care for triple-negative first-line cancers A phase III trial comparing Dato-DXd vs. chemotherapy in patients with untreated metastatic/recurrent TNBC who were ineligible for ICI. @OncoAlert #ESMO25 #bcsm"
X Link @Dr_Oncologista 2025-10-19T10:01Z 1252 followers, 2543 engagements
"PSMAddition Scott Tagawa presents PIII trial of Lu-PSMa -XXX + ADT + ARPI in PSMA positive HSPC Discrete gain in SLPr immature SG @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-19T16:21Z 1252 followers, XXX engagements
"🔹Innovative molecule with demonstrated efficacy control with XX Chinese that performed the same as KN407 still without OS data. 🔹 The global HARMONI-3 study of 1L NSCLC independent of histology is awaited for confirmation and validation of the data. @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-20T06:36Z 1254 followers, XXX engagements
"PSMAddition 1st line castration-sensitive metastatic prostate cancer Androgen Deprivation Therapy Antiandrogen Therapy +/- Lutecio177-PSMA617 Significant benefit for radiological progression-free survival ➡ Immature Overall Survival @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-20T07:01Z 1254 followers, XXX engagements
"Low TGI oral session CHECKMATE 8HW data updated Result only for 1st line IPI + NIVO with relevant numerical difference in SLP in relative to NIVO Global Survival (Here in all tto lines ) Still Immature Breakwater analysis according to CTDNA dynamics @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-20T11:05Z 1252 followers, 1664 engagements
"the beautiful data from POSITIVE now mature at X yrs Dr. Fedro Peccatori and this group of young #BreastCancer experts are conducting one of the most exciting studies of the decade. @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T01:39Z 1244 followers, XXX engagements
"evERA-BC trial; Giredestrant (oral SERD) + everolimus vs SOC ET + everolimus in ER+/HER2 advanced breast cancer previously treated with CDK4/6i ESR1m population: median PFS XXXX vs XXXX mo HR XXXX (p0.0001) @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T08:31Z 1237 followers, XXX engagements
"evERA very interesting study competitive with the main combination in this scenario at the moment: Imlu + Abema (EMBER-3) First phase X to evaluate the oral SERD + mTOR inhibitor combination In a population of post-PD patients iCDK4/6 @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T14:04Z 1245 followers, XXX engagements
"Establishing a new standard of care DESTINY-Breast05 A phase III trial comparing T-DXd (trastuzumab deruxtecan) vs. T-DM1 in high-risk HER2-positive early breast cancer with residual invasive disease (non-pCR) after neoadjuvant chemotherapy. @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T15:25Z 1245 followers, XXX engagements
"Results after CDK4/6 inhibitor treatment including the VIKTORIA-1 and eveERA-BC trials #ESMO25 @OncoAlert"
X Link @Dr_Oncologista 2025-10-18T08:55Z 1247 followers, XXX engagements
"OptiTROP-Breast02 Chinese study with new anti-TROP2 ADC after depleting HT in RH+ patients. Sacituzumab tirumotecan Results from the randomized multi-center phase Ill #ESMO25 @OncoAlert"
X Link @Dr_Oncologista 2025-10-18T12:09Z 1247 followers, XXX engagements
"evERA very interesting study competitive with the main combination in this scenario at the moment: Imlu + Abema (EMBER-3) First phase X to evaluate the oral SERD + mTOR inhibitor combination In a population of post-PD patients iCDK4/6"
X Link @Dr_Oncologista 2025-10-18T14:01Z 1247 followers, XXX engagements
"CARES-009 phase X study of perioperative camrelizumab and rivoceranib for HCC And data on perioperative immunotherapy and antiangiogenic therapy in HCC X cycles of preoperative Camrelizumab and Rivoceranib @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-19T11:11Z 1246 followers, XXX engagements
"Positive study for PFS with gain compared to QT-10 regardless of the PD-L1 status assessed OS still immature safety data without significant increase in AE including bleeding risk"
X Link @Dr_Oncologista 2025-10-20T06:35Z 1247 followers, XX engagements
"FOG001 a beta-catenin TCF interaction inhibitor is effective in treating desmoid tumors even in patients previously treated with gamma-secretase inhibitors. It's showing promise. @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-17T15:56Z 1252 followers, XXX engagements
"DeLLphi-303: Phase 1b study evaluating tarlatamab combined with CT+10 in extensive small cell lung disease 🔹Interesting SG result in 1st @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T10:14Z 1252 followers, XXX engagements
"A new standard of care for first-line triple-negative chemotherapy ASENT-03 Study: A Phase III trial comparing sacituzumab govitecan (SG)** with chemotherapy in patients with untreated metastatic TNBC who are ineligible for PD-L1 inhibitors @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-19T10:06Z 1254 followers, XXX engagements
"Richard Finn presents the results of phase X IMbrave152/SkYSCRAPER-14 study at @myESMO Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced HCC @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-19T11:16Z 1252 followers, XXX engagements
"OptiTROP-Lung04 Sacituzumab Tirumotecan an anti-TROP2 ADC in 2L in EGFRmut NSCLC after PD to TKI Without TROP2 biomarker analysis XX% received 3rd Generation TKI Positive study for PFS and OS with median not reached with XX% risk reduction @OncoAlert #ESMO25 #lcsm"
X Link @Dr_Oncologista 2025-10-20T06:45Z 1252 followers, XXX engagements
"Advanced Bladder Cancer 1st line and HER2 expressed 1+ 2+ or 3+ Disitamabe Vedotin + Toripalimabe VSplatinum-based QT Significant benefit in SLP Some HER2 expression is present in up to XX% of cases Enriched in high urothelial treatment @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-20T07:16Z 1252 followers, XXX engagements
"Encouraging Results for VT3989 in Advanced Solid Tumors Phase 1/2 study (NCT04665206) of VT3989 (a YAP/TEAD inhibitor) shows promising data: Strong Efficacy: Broad tumor shrinkage observed in mesothelioma patients at the optimized dose. @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-20T08:18Z 1252 followers, XXX engagements
"The QT interval appears to be important for improving ctDNA clearance and reducing the emergence of known resistant variants. The question is: Is this situation sustainable and does it relate to as-yet-unknown variants ZANZALITINIBE =TKI MULTIKINASE ATEZOLIZUMABE= ANTI PD-L1"
X Link @Dr_Oncologista 2025-10-20T11:05Z 1252 followers, XX engagements
"Phase III study of adjuvant ensartinib versus placebo for surgically resected ALK+ mutant non-small cell lung cancer (NSCLC). Ensartinib demonstrated a significant and statistically significant clinical and progression-free survival (DFS) benefit @OncoAlert #ESMO25 @Lung_Cancers"
X Link @Dr_Oncologista 2025-10-20T13:30Z 1254 followers, XXX engagements
"MonarchE trial - X year abemaciclib in early #breastcancer - shows a survival benefit (1.8% difference at X yrs) I was glad to see granularity in post-recurrence therapy data which are key in interpretating any survival benefit #ESMO25 @OncoAlert @myESMO #bcsm"
X Link @Dr_Oncologista 2025-10-17T15:50Z 1246 followers, XXX engagements
"The effects of HDAC inhibitors and PD-1 inhibitors. In liposarcoma the response rate was XX% for well-differentiated and dedifferentiated tumors. It is difficult to explain biologically why the combination is so effective @OncoAlert @myESMO #ESMO25"
X Link @Dr_Oncologista 2025-10-17T15:54Z 1246 followers, XXX engagements
"Study evaluating multidisciplinary discussion (MDT) followed by induction chemotherapy + IO X XX and new MDT Most patients even those borderline for resection were operated on after QT + XX induction @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T10:25Z 1246 followers, XXX engagements
"Presidential EVP from KN905 in MIBC at @myESMO with incredibly strong data. PathCR of XX% EFS and OS positive a game changing study continuation of treatment with EV in those with pCR Is cisplatin candidacy still relevant for MIBC @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-18T17:41Z 1247 followers, XXX engagements
"DESTINY-Breast09 Updated PFS data in subgroup analysis of TDXd in 1L in HER2+ First presentation of efficacy data at this yrs ASCO CHAIRS RUPERT BARTSCH SEOCK @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-19T09:48Z 1247 followers, XXX engagements
"ASENT-03 Study Sacituzumab Govitecan anti-TROP2 in 1L in TNBC not a candidate for immunotherapy It is worth noting that patients with a recurrence interval 6m were not included but the crossover allowed is beneficial since Saci-Gov has gained OS in 2L. @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-19T10:17Z 1247 followers, XXX engagements
"HARMONI-6 Study of Ivonescimab +QT versus 10+QT 1L in patients with PD-L1-independent squamous NSCLC in a Chinese population 🔹Independent of PD-L1 in Chinese population @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-20T06:35Z 1247 followers, XXX engagements
"future treatment of this patient population relies on combinations of novel SERDs/SERMs with other targeted agents particularly those inhibiting the PI3K/AKT/mTOR signaling pathway to successfully bypass the conventional 6-month PFS threshold. @OncoAlert #ESMO25"
X Link @Dr_Oncologista 2025-10-21T09:28Z 1254 followers, 1275 engagements